People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| ADARx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $352.5M | $2.8B | 2020 |
| Janux Therapeutics, Inc. | — | Biotechnology | Series D+ | $192.4M | $4.0B | 2021 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2012 |
| Lila Biologics, Inc. | — | Biotechnology | Series A | $9.5M | $73.6M | 2023 |
| Prana Therapies, Inc. | — | Biotechnology | Series A | $5.0M | $27.4M | 2024 |
Sheila Gujrathi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sheila Gujrathi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Simeon George | 1 | 8 |
| Judith Li | 1 | 8 |
| Chen Yu | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Tighe Reardon | 1 | 7 |
| Robert Nelson | 1 | 7 |
| Doug Cole | 1 | 6 |
| PAUL Grayson | 1 | 5 |
| Jay Lichter, Ph.D. | 1 | 5 |
| Faheem Hasnain | 1 | 5 |
| Lorence Kim | 1 | 5 |
| Hongbo Lu | 1 | 4 |
| William Rastetter | 1 | 4 |
| Vickie L. Capps | 1 | 3 |
| James Schmidt | 1 | 3 |
| Raymond Stevens | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.